A solution to the availability and cost of drugs in poorer countries? Comment 02 February 2013 Pages: 2 - 2
Budesonide recommended as first-line therapy for mild to moderate Crohn's disease Media release 02 February 2013 Pages: 2 - 2
Updates to NCCN cancer- and treatment-related anaemia guidelines Media release 02 February 2013 Pages: 2 - 2
Capping drug benefits does not reduce total medical costs Clinical study 02 February 2013 Pages: 4 - 4
Salmeterol/fluticasone cost effectiveness “compares favorably” Clinical study 02 February 2013 Pages: 4 - 4
Hepatitis B vaccination coverage increased among US adults Clinical study 02 February 2013 Pages: 5 - 5
Alzheimer's disease: clinical features may affect disease costs Clinical study 02 February 2013 Pages: 6 - 6
Less healthcare resource use with valsartan than with metoprolol Clinical study 02 February 2013 Pages: 6 - 6
Antihypertensive prescribing changing in elderly Canadians Clinical study 02 February 2013 Pages: 7 - 7
CDC recommendations: adherence difficult to improve in otitis media Clinical study 02 February 2013 Pages: 7 - 7
Intensive atorvastatin the ideal choice in coronary disorders Clinical study 02 February 2013 Pages: 7 - 7
Lifetime treatment costs remain stable for children with HIV Clinical study 02 February 2013 Pages: 7 - 7
Use of the candidiasis peptide nucleic acid fluorescence in situ hybridisation (PNA FISH) test is cost-saving relative to the candidiasis screen test Clinical study 02 February 2013 Pages: 8 - 8
SSRIs, TCAs and lofepramine: no difference in cost effectiveness Clinical study 02 February 2013 Pages: 8 - 8
Lenograstim + chemo for SCLC: cost effectiveness “finely balanced” Clinical study 02 February 2013 Pages: 9 - 9
Piperacillin/tazobactam infusions: continuous or intermittent? Clinical study 02 February 2013 Pages: 9 - 9
Four Ranbaxy antiretrovirals added to WHO prequalification list News item 02 February 2013 Pages: 11 - 11